Ignite Creation Date:
2024-05-05 @ 5:27 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00452413
Status:
COMPLETED
Last Update Posted:
2021-05-13
First Post:
2007-03-23
Brief Title:
A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase 12 Trial of Enzastaurin and Erlotinib in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer NSCLC After Prior Chemotherapy
Status:
COMPLETED
Status Verified Date:
2021-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I A study to see what doses of Enzastaurin and Erlotinib are best tolerated by participants with solid tumor cancer
Phase II A study to see how long participants with non-small cell lung cancer NSCLC treated with Enzastaurin and Erlotinib live
Phase II A study to see how long participants with non-small cell lung cancer NSCLC treated with Enzastaurin and Erlotinib live
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H6Q-MC-S030 | OTHER | Eli Lilly and Company | None |